ALMDT Median Technologies

Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) candidates for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers, today announced that it will attend the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago, IL, USA, from Dec. 1-5. Median iCRO and eyonis™ teams will welcome interested parties at Booth #5442, AI Showcase, South Hall, Level 3, from December 1-4 (technical exhibits dates).

The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD) as well as the most recent advances for iCRO central and AI-powered oncology trial imaging services for pharmaceutical companies.

Median in August that its investigational lung cancer diagnostic SaMD, eyonis™ LCS, met all primary and secondary endpoints with statistical significance in REALITY (), the first of the two pivotal eyonis™ LCS clinical studies. This impressive result was achieved despite the inclusion of many challenging Low Dose Computed Tomography (LDCT) images. Median recently held a data featuring two globally leading U.S. pulmonologists.

“We are pleased to present the eyonis™ LCS data at RSNA. The recently reported REALITY study data suggest that eyonis™ LCS may well be a game changer, significantly improving early diagnosis and allowing for life-saving earlier intervention and broader screening access. Our diagnostic device may be a critical catalyst facilitating global implementation of these lifesaving screening programs. Based on our strong data, we are now looking towards our filings for marketing authorization, in both the US and Europe, in H1 2025, as soon as we receive and report the data from RELIVE, our second pivotal study in Q1 2025,” said Fredrik Brag, CEO of Median Technologies.

Median eyonis™ team will present at RSNA:

  • Scientific Poster Presentation:

Session: Chest Imaging (T2-SPCH-2)

Scientific poster discussion on Tuesday, December 3rd, 9:00 AM - 9:30 AM CST

Learning Center, East, Level 3

  • Industry Presentation:

Session: AI-Theater Presentation (IT5-AI105)

Tuesday, December 3rd, 12:30 PM - 12:50 PM CST

AI Theater, Booth 5536, South Hall, Level 3

About eyonis™ LCS: eyonis™ Lung Cancer Screening (LCS) is an artificial intelligence (AI) powered diagnostic device that uses machine learning to help analyze imaging data generated with low dose computed tomography (LDCT) to diagnose lung cancer at the earliest stages, when it can still be cured in many patients. eyonis™ LCS has been classified by regulators as “Software as a Medical Device”, or SaMD, and is the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY (() (successfully completed)) and RELIVE (ongoing). Filing applications including these pivotal data are scheduled to be submitted for FDA 510(k) premarket clearance and CE marking in 2025. Separately, Median’s AI technology is being sold and deployed across cancer indications, via Median’s iCRO business unit, to companies performing clinical trials of experimental therapeutics, including the world’s leading pharmaceutical companies in cancer.

About RSNA Annual Meeting: The Radiological Society of North America Annual Meeting is the largest medical imaging conference in the world, featuring over 300 educational courses and more than 2,800 scientific presentations covering every subspecialty. RSNA 2024 is expecting approximately 50,000 medical imaging professionals, representing over 120 countries. RSNA hosts the largest medical equipment exhibition, featuring products and services from almost 700 manufacturers, suppliers and developers from innovative startups to industry giants. For more information about the RSNA 2024 Annual Meeting, visit

About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit .

EN
26/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

 PRESS RELEASE

Median Technologies: Financial Communications Schedule for the First H...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results:   Publication     Date   2024 results     April 29, 2025* *Distribution after the close of trading About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysi...

 PRESS RELEASE

Median Technologies : Calendrier de communication financière du premie...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME), annonce la date de publication de ses résultats 2024 : Publication         Date Résultats 2024         29 avril 2025* *Diffusion après clôture des marchés A propos de Median Technologies : Pionnière dans les logiciels dispositifs médicaux et services d’imagerie innovants, Median Technologies exploite les technologies de pointe d’Intelligence Artificielle pour augmenter la précision des diag...

 PRESS RELEASE

Median Technologies : Bilan semestriel du contrat de liquidité

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Au titre du contrat de liquidité portant sur les actions de la société Median Technologies (FR0011049824, ALMDT, éligible au plan PEA/PME, “Median” ou “la Société”) confié à TP ICAP (Europe), les moyens suivants figuraient au compte de liquidité à la date du 31/12/2024 : 30 559 titres 134 615,99 Euros en espèce. Au cours du second semestre 2024, il a été négocié un total de : ACHAT 253 462 titres 1 060 310,22 EUR 488 transactions VENTE 259 038 titres 1 107 913,49 EUR 452 tran...

 PRESS RELEASE

Median Technologies : Déclaration du nombre total de droits de vote et...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (Paris:ALMDT) : Nombre d'actions composant le capital 18 516 983 Nombre réel de droits de vote* (déduction faite des actions auto-détenues**) 18 463 224 Nombre théorique des droits de vote* (y compris actions auto-détenues**) 18 493 783 (*) Les actions de préférence de catégorie E sont sans droits de vote (**) En application de l’article 223-11 du Règlement Général de l’Autorité des Marchés Financiers A propos de Median Technologies : Pionnière dans les solutions et...

 PRESS RELEASE

Median Technologies : Déclaration du nombre total de droits de vote et...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (Paris:ALMDT): Nombre d'actions composant le capital 18 516 983 Nombre réel de droits de vote* (déduction faite des actions auto-détenues**) 18 457 997 Nombre théorique des droits de vote* (y compris actions auto-détenues**) 18 493 783 (*) Les actions de préférence de catégorie E sont sans droits de vote (**) En application de l’article 223-11 du Règlement Général de l’Autorité des Marchés Financiers A propos de Median Technologies : Pionnière dans les solutions et ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch